This chapter highlights contributions to the body of knowledge in kidney transplant for 2012. Specifically, we focus on new developments in alloantibody and chronic allograft injury research. Also, we discuss new immunosuppressant agent trial results. One important new immunosuppressant we cover is belatacept, the first new FDA approved immunosuppressant in many years. Finally, we discuss some key peripheral studies that made 2012 an exciting year in kidney transplant research.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 2012|